通过靶向抗体治疗改善慢性淋巴细胞白血病患者的治疗效果。
Improving the treatment outcome of patients with chronic lymphocytic leukemia through targeted antibody therapy.
机构信息
Division of Hematology, Department of Internal Medicine, The Arthur G. James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
出版信息
Hematol Oncol Clin North Am. 2013 Apr;27(2):303-27. doi: 10.1016/j.hoc.2012.12.003.
Therapy for chronic lymphocytic leukemia (CLL) has evolved dramatically throughout the years. In 1997, rituximab (Rituxan), a CD20 monoclonal antibody (mAb), became the first mAb approved by the Food and Drug Administration for marketing in the treatment of cancer, specifically targeting B-cell malignancies. Over the last 10 years, rituximab or other mAbs including alemtuzumab and ofatumumab have become an integral part of the standard of care for CLL patients as single agents or in combination with chemotherapy or other immunotherapy. This review discusses the currently approved and novel mAbs for the treatment of CLL.
慢性淋巴细胞白血病 (CLL) 的治疗方法多年来发生了巨大变化。1997 年，利妥昔单抗（Rituxan），一种 CD20 单克隆抗体 (mAb)，成为食品和药物管理局批准的第一种用于治疗癌症的 mAb，专门针对 B 细胞恶性肿瘤。在过去的 10 年中，利妥昔单抗或其他 mAbs，包括阿仑单抗和奥法木单抗，已成为 CLL 患者标准治疗的重要组成部分，无论是作为单一药物还是与化疗或其他免疫疗法联合使用。这篇综述讨论了目前批准用于治疗 CLL 的新型 mAbs。
Zotero 插件